Abstract:Alzheimer's disease (AD) is the most common form of dementia, and the molecular mechanisms that underlie AD pathophysiology remain unclear. AMP-activated protein kinase (AMPK) is a Ser/Thr kinase that functions as a central energy sensor to maintain cellular energy homeostasis. Furthermore, AMPK integrates several signaling pathways controlling de novo protein synthesis (mRNA translation) which is vital for long-term synaptic plasticity and memory formation. Dysregulation of energy homeostasis and de novo protein synthesis are both implicated in AD. AMPK is a heterotrimeric protein with a catalytic α subunit and regulatory β/γ subunit. The α subunit of AMPK exists in two isoforms: α1 and α2, and their roles in AD are unknown. Post Mortem brain tissue from human AD was examined by both western blot and immunohistochemistry for AMPKα1 and AMPKα2 levels. AMPKα1 protein levels were selectively reduced in late development in the forebrain of Tg19959 AD model mice to generate AMPKα1(+/-)/Tg19959 double mutant mice. These mice were cognitively assessed by Morris Water Maze (MWM) and Novel Object Recognition (NOR) tasks. Hippocampal long-term potentiation (LTP) was measured to assess synaptic plasticity, moreover dendritic spine morphology was examined by Golgi Stain. In human hippocampal tissue AMPKα1 levels were dramatically increased, while levels of AMPKα2 were decreased in comparison with age-matched controls. These changes were neuronally localized and AD hippocampi specific. AD associated impairments of cognition and synaptic plasticity were alleviated in AMPKα1(+/-)/Tg19959 double mutant mice. Analysis of dendritic spine morphology revealed the hippocampal abnormalities in theTg19959 model mice were restored with genetic reduction of AMPKα1. AMPKα1 is abnormally neuronally upregulated in AD. Our results demonstrate that restoration of AMPKα1 levels in an AD model mouse ameliorates the behavioral and synaptic plasticity impairments. Our findings indicate AMPKα1 dysregulation as a molecular mechanism underlying AD pathophysiology, and providing insights into a potential therapeutic strategy.

Dysregulation of the mTOR Pathway Mediates Impairment of Synaptic Plasticity in a Mouse Model of Alzheimer's Disease

Dysregulated mTOR networks in experimental sporadic Alzheimer's disease

Mammalian Target of Rapamycin (mTor) Mediates Tau Protein Dyshomeostasis: IMPLICATION FOR ALZHEIMER DISEASE

Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid β.

Inhibition of AMP-Activated Protein Kinase Signaling Alleviates Impairments in Hippocampal Synaptic Plasticity Induced by Amyloid Β

Cerebral Mtor Signal and Pro-Inflammatory Cytokines in Alzheimer's Disease Rats.

Targeting the Mtor Signaling Network for Alzheimer'S Disease Therapy

Dysregulation of Neuronal Protein Synthesis in Alzheimer’s Disease

Akt activation ameliorates deficits in hippocampal-dependent memory and activity-dependent synaptic protein synthesis in an Alzheimer’s disease mouse model

Elucidating the role of DEPTOR in Alzheimer’s disease

mTOR inhibition alleviated tau phosphorylation-induced mitochondrial impairment, oxidative stress, and cognitive impairment

Pharmacological mTOR inhibitors in ameliorating Alzheimer's disease: current review and perspectives

mTOR inhibition enhances synaptic and mitochondrial function in Alzheimer's disease in an APOE genotype-dependent manner

P2‐157: BRAIN‐SPECIFIC REPRESSION OF AMPKα1 ALLEVIATES MEMORY DEFICITS AND SYNAPTIC FAILURE IN A MOUSE MODEL OF ALZHEIMER'S DISEASE

Dysregulating mTORC1-4E-BP2 signaling in GABAergic interneurons impairs hippocampus-dependent learning and memory

Isoform-specific Effects of Neuronal Inhibition of AMPK Catalytic Subunit on LTD Impairments in a Mouse Model of Alzheimer’s Disease

Regulation of tau by mTor

Dysregulated CRTC1-BDNF signaling pathway in the hippocampus contributes to Aβ oligomer-induced long-term synaptic plasticity and memory impairment

Repression of the eIF2α kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease.

Translational control of microglial inflammatory and neurodegenerative responses

Suppression of the Kinase for Elongation Factor 2 Alleviates Mglur-Ltd Impairments in a Mouse Model of Alzheimer's Disease.